Welcome to the e-CCO Library!

DOP83: Association of FUT2 and ABO with Crohn’s disease in Koreans
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

H-S. Lee*1,2, B. M. Kim2, S. Jung2, M. Hong2, K. Kim2, J. W. Moon2, J. Baek2, S. W. Hwang3, S. H. Park3, S-K. Yang3, K. Song2, B. D. Ye3

Created: Friday, 22 February 2019, 9:41 AM
DOP83: Efficacy and Safety of Ustekinumab for Ulcerative Colitis Through 3 Years: UNIFI Long-term Extension
Year: 2021
Source: ECCO'21 Virtual
Authors: Abreu, M.T.(1);Danese, S.(2);Sandborn, W.J.(3);Miao, Y.(4);Tikhonov, I.(4);Zhang, H.(4);Panaccione, R.(5);Hisamatsu, T.(6);Scherl, E.J.(7);Leong, R.W.(8);Rowbotham, D.S.(9);Arasaradnam, R.P.(10);Afif, W.(11);Peyrin-Biroulet, L.(12);Sands, B.E.(13);Marano, C.(4)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP83: Normalisation of biomarkers and improvement in clinical outcomes in patients with Crohn’s Disease treated with risankizumab in the phase 3 ADVANCE, MOTIVATE, and FORTIFY studies
Year: 2022
Source: ECCO'22
Authors: Atreya, R.(1);Feagan, B.(2);Shchukina, O.(3);Jairath, V.(4);Rieder, F.(5);Hisamatsu, T.(6);Siegmund, B.(7);Rizzo, J.(8);Kligys, K.(8);Neimark, E.(8);Song, A.(8);Zambrano, J.(8);Mallick, M.(8);Cheng, E.(8);Armuzzi, A.(9);
Created: Friday, 11 February 2022, 3:52 PM
DOP83: Proactive dosing is superior to clinically based dosing in terms of endoscopic healing in paediatric patients with Crohn's disease receiving maintenance infliximab: A randomized controlled trial
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Kang, B.(1)*;Moon, J.S.(2);Lee, Y.J.(3);Kim, M.J.(4);Choe, B.H.(1);Ko, J.S.(2);Park, J.H.(3);Choe, Y.H.(4);
Created: Friday, 14 July 2023, 10:43 AM
DOP84 Crohn’s disease modifies the DNA methylome of human adipose-stem cells, which is only partially re-established in remission
Year: 2020
Source:

ECCO'20 Vienna

Authors:

C. Serena1, M. Millan2, M. Ejarque1, A. Saera-Vila1, D. Monfort-Ferré1, M. Bautista3, M. Menacho3, M. Martí4, E. Espin4, J. Vendrell1, S. Fernández-Veledo1

Created: Thursday, 30 January 2020, 10:12 AM
DOP84: Early treatment responses within 14 days of intravenous vedolizumab induction therapy for Crohn’s Disease: Post hoc analysis of patient-reported outcomes from the VISIBLE 2 study
Year: 2021
Source: ECCO'21 Virtual
Authors: D'Haens, G.(1);Baert, F.(2);Danese, S.(3);Kobayashi, T.(4);Loftus Jr., E.V.(5);Sandborn, W.J.(6);Dornic, Q.(7);Lindner, D.(7);Kisfalvi, K.(8);Marins, E.G.(8);Vermeire, S.(9)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP84: IBD-related hospitalization and surgery rates in biologic-naïve patients with IBD treated with vedolizumab versus other biologics: Results from a long-term, prospective, observational study
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Sebastian, S.(1)*;Siegel, C.(2);Siegmund, B.(3);Zhou, J.(4);Jones, S.(5);Adsul, S.(4);Louis, E.(6);
Created: Friday, 14 July 2023, 10:43 AM
DOP84: Nationwide incidence and prevalence of paediatric inflammatory bowel disease in Scotland 2015–2017 demonstrates the highest paediatric prevalence rate recorded worldwide
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

C. Burgess*1,2, P. Henderson1,2, I. Chalmers3, R. Harris4, R. Hansen4, R. Russell4, D. Wilson1,2

Created: Friday, 22 February 2019, 9:41 AM
DOP84: Risankizumab maintenance therapy results in sustained improvements in endoscopic outcomes in patients with moderate to severe Crohn’s Disease: Post-hoc analysis from the phase 3 study FORTIFY
Year: 2022
Source: ECCO'22
Authors: Irving, P.M.(1);Abreu, M.(2);Axler, J.(3);Gao, X.(4);Torres, J.(5);Neimark, E.(6);Song, A.(7);Wallace, K.(7);Kligys, K.(8);Berg, S.(8);Liao, X.(7);Panaccione, R.(9);
Created: Friday, 11 February 2022, 3:52 PM
DOP85 The role of fibroblasts in the pathogenesis of Crohn’s disease-associated fistulas and in mesenchymal stem cell therapy
Year: 2020
Source:

ECCO'20 Vienna

Authors:

R.S. Bruckner1, M.C. Barnhoorn1, H. Mei2, S.M. Kiełbasa2, T.J. Harrijvan1, S.K. Hakuno1, J.J. van der Reijden1, A.E. van der Meulen-de Jong1, L.J.A.C. Hawinkels1

Created: Thursday, 30 January 2020, 10:12 AM
DOP85: Corticosteroid-free efficacy and safety outcomes in patients receiving tofacitinib in the OCTAVE Sustain maintenance study
Year: 2021
Source: ECCO'21 Virtual
Authors: Vavricka, S.R.(1);Greuter, T.(2);Cohen, B.L.(3);Reinisch, W.(4);Steinwurz, F.(5);Fellmann, M.(6);Guo, X.(7);Lawendy, N.(7);Paulissen, J.(8);Peyrin-Biroulet, L.(9)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP85: Crohn's Disease Strictures Respond to Drug Treatment and Treat-to-Target Intense Combination Therapy is More Effective than Standard Anti-TNF Therapy. Two year results of the STRIDENT Randomised Controlled Trial.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Schulberg, J.(1,2)*;Hamilton, A.(1,2);Wright, E.K.(1,2);Holt, B.(1,2);Lovett, G.(1,2);Sutherland, T.(2,3);Ross, A.(1);Vogrin, S.(2);Kamm, M.(1,2);
Created: Friday, 14 July 2023, 10:43 AM
DOP85: Efficacy of risankizumab rescue therapy in patients with moderately to severely active Crohn’s Disease and inadequate response to risankizumab maintenance therapy
Year: 2022
Source: ECCO'22
Authors: Baert, F.J.(1);Atreya, R.(2);Kakuta, Y.(3);Long, M.(4);Roblin, X.(5);Neimark, E.(6);Song, A.(6);Wallace, K.(6);Kingys, K.(6);Mallick, M.(6);Liao, X.(6);Lim, A.(7);
Created: Friday, 11 February 2022, 3:52 PM
DOP85: Rising depression and antidepressant use amongst inflammatory bowel disease patients
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

J. Blackwell*1, S. Saxena2, C. Alexakis1, E. Cecil2, A. Bottle2, I. Petersen3,4, M. Hotopf5, R. Pollok1

Created: Friday, 22 February 2019, 9:41 AM
DOP86 An IFN-STAT1-MLKL axis drives programmed necrosis of Paneth cells in Crohn’s ileitis
Year: 2020
Source:

ECCO'20 Vienna

Authors:

L. HARTMANN1, B. Siegmund2, C. Weidinger2, C. Becker1, M.F. Neurath1, C. Günther1

Created: Thursday, 30 January 2020, 10:12 AM
DOP86: Corticosteroid-sparing effects of ustekinumab therapy for Ulcerative Colitis through 3 years: UNIFI long-term extension
Year: 2021
Source: ECCO'21 Virtual
Authors: Scherl, E.J.(1);Rowbotham, D.S.(2);Danese, S.(3);Sandborn, W.J.(4);Miao, Y.(5);Zhang, H.(5);Abreu, M.T.(6);Panaccione, R.(7);Afif, W.(8);Hisamatsu, T.(9);Leong, R.W.(10);Arasaradnam, R.P.(11);Sands, B.E.(12);Marano, C.(5)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP86: Mirikizumab-induced upregulation of colonic transcripts correlates with improvements in stool frequency in a phase 2 study of patients with moderately to severely active Ulcerative Colitis
Year: 2022
Source: ECCO'22
Authors: Steere, B.(1);Powell, N.(2);Higgs, R.(1);Wang, Y.C.(1);Milch, C.(1);Sandborn, W.J.(3);Sands, B.E.(4);Reinisch, W.(5);D'Haens, G.(6);Krishnan, G.(1);
Created: Friday, 11 February 2022, 3:52 PM
DOP86: Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn's disease: A phase 3, randomised, placebo-controlled study (LIBERTY-CD).
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Colombel, J.F.(1)*;Hanauer, S.B.(2);Sandborn, W.(3);Sands, B.E.(4);Schreiber, S.(5);Danese, S.(6);Kierkus, J.(7);Kulynych, R.(8);Klopocka, M.(9);Lahat, A.(10);Gonciarz, M.(11);Osipenko, M.(12);Borzan, V.(13);Kowalski, M.(14);Saenko, D.(15);Sardinov, R.(16);Kim, S.(17);Bae, Y.(17);Lee, S.(17);Yang, S.(17);Lee, J.(17);Lee, S.J.(18);Lee, S.G.(18);Park, G.(18);
Created: Friday, 14 July 2023, 10:43 AM
DOP87 SUCNR1 a novel key protagonist in fistula development
Year: 2020
Source:

ECCO'20 Vienna

Authors:

C. Bauset1, L. Gisbert-Ferrandiz1, D. Ortiz-Masia2, S. Coll1, C. Mamie3, M. Scharl3, S. Calatayud1, M.D. Barrachina1, J. Cosín-Roger4

Created: Thursday, 30 January 2020, 10:12 AM